In breast tumour pathology, there is a well-known perplexing phenomena in which the ductal carcinoma in situ (DCIS) often shows a much higher frequency of HER2 gene amplification and overexpression than that of the invasive breast cancer (50–60% versus 20–30%) 1–7. The gene discussed is ERBB2; the disease is invasive breast carcinoma.